Abelacimab for high‐risk atrial fibrillation patients
Part of Heart & circulation clinical trials.
This trial is a follow-up (extension) for people with atrial fibrillation who are already taking the study medicine abelacimab to see if it stays safe and effective. It's for those who have finished the first part and want to keep going.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be able to give written permission to join this part of the study
- You must still be taking the study medicine at the end of the first part of the study
- You must not have any serious health condition that could make the study risky for you
- You must not be allergic to the study drug or similar medicines
- You must not have a mental health or medical issue that would require urgent care or stop you from following the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests whether abelacimab can prevent stroke and other blood-clot problems in people with atrial fibrillation (or atrial flutter) who cannot safely take usual mouth blood thinners. It also looks at safety, especially bleeding risk.
This study is for people with atrial fibrillation who are planning to have a catheter ablation procedure. It will look at how well the heart works after the procedure and how to prevent future events.
This study tests a new combination treatment approach for people with long-standing persistent atrial fibrillation (a type of irregular heartbeat that lasts for years). It aims to see if this approach can help improve symptoms and restore a more normal heart rhythm.
This trial tests whether using a special heart-mapping device during ablation (a procedure to fix irregular heartbeats) can improve outcomes for people with persistent atrial fibrillation and an enlarged left heart chamber.
This trial tests whether taking a cholesterol-lowering medicine called ezetimibe alongside the usual care can help prevent atrial fibrillation from coming back after a procedure called catheter ablation. Catheter ablation is a treatment that uses heat or cold to destroy tiny areas of heart tissue that cause irregular heartbeats. For people with persistent atrial fibrillation, this trial may offer a way to improve the long-term success of the ablation.
This trial tests whether an early procedure (catheter ablation) for atrial fibrillation (AF) can prevent strokes in people with a high risk of stroke. The goal is to see if this treatment is safer and more effective than standard care for patients with other health conditions.
Hear when a new Atrial Fibrillation (AF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.